Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds
Earlier this month, Reshma Kewalramani took over the reins as Vertex Pharmaceuticals’ CEO — she will now be tasked with grappling with criticism from cost-effectiveness watchdog ICER, which on Monday issued a report suggesting that despite the health gains offered by its suite of cystic fibrosis drugs, their prices are far too high to be sustainable for patients and health care systems.
“Despite being transformative therapies, the prices set by the manufacturer – costing many millions of dollars over the lifetime of an average patient – are out of proportion to their substantial benefits,” said David Rind, ICER’s chief medical officer in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.